secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapsoVision, Inc (CV)
CIK:        0001378325
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001378325-26-000008
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CapsoVision reports 15% revenue growth in FY2025; completes $14M private placement
--------------------------------------------------------------------------------

- Q4 2025 revenue $3.9M (+13% YoY); full year $13.6M (+15% YoY) driven by higher capsule sales.
- Gross margin stable at 50% Q4 and 53% full year (vs 54% prior year).
- Operating expenses $9.4M Q4 (+$3.0M YoY); full year $32.7M (+$6.4M) on CMOS sensor development and public company costs.
- Cash $10.1M at Dec 31, 2025; completed $14M private placement in March 2026.
- Submitted FDA 510(k) for AI-assisted module; 161,000+ patients used CapsoCam Plus as of Dec 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1378325/000137832526000008/0001378325-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1378325/000137832526000008/cv-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001378325-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer